1. Home
  2. DSGN vs MLP Comparison

DSGN vs MLP Comparison

Compare DSGN & MLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • MLP
  • Stock Information
  • Founded
  • DSGN 2017
  • MLP 1909
  • Country
  • DSGN United States
  • MLP United States
  • Employees
  • DSGN N/A
  • MLP N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • MLP Real Estate
  • Sector
  • DSGN Health Care
  • MLP Finance
  • Exchange
  • DSGN Nasdaq
  • MLP Nasdaq
  • Market Cap
  • DSGN 348.2M
  • MLP 411.7M
  • IPO Year
  • DSGN 2021
  • MLP 1972
  • Fundamental
  • Price
  • DSGN $4.21
  • MLP $17.95
  • Analyst Decision
  • DSGN Buy
  • MLP
  • Analyst Count
  • DSGN 2
  • MLP 0
  • Target Price
  • DSGN $8.00
  • MLP N/A
  • AVG Volume (30 Days)
  • DSGN 156.4K
  • MLP 14.9K
  • Earning Date
  • DSGN 03-10-2025
  • MLP 05-12-2025
  • Dividend Yield
  • DSGN N/A
  • MLP N/A
  • EPS Growth
  • DSGN N/A
  • MLP N/A
  • EPS
  • DSGN N/A
  • MLP N/A
  • Revenue
  • DSGN N/A
  • MLP $12,196,000.00
  • Revenue This Year
  • DSGN N/A
  • MLP N/A
  • Revenue Next Year
  • DSGN N/A
  • MLP N/A
  • P/E Ratio
  • DSGN N/A
  • MLP N/A
  • Revenue Growth
  • DSGN N/A
  • MLP 34.84
  • 52 Week Low
  • DSGN $3.15
  • MLP $17.02
  • 52 Week High
  • DSGN $7.77
  • MLP $26.46
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 40.65
  • MLP 40.12
  • Support Level
  • DSGN $4.06
  • MLP $17.76
  • Resistance Level
  • DSGN $5.09
  • MLP $18.47
  • Average True Range (ATR)
  • DSGN 0.38
  • MLP 0.56
  • MACD
  • DSGN -0.08
  • MLP 0.05
  • Stochastic Oscillator
  • DSGN 9.93
  • MLP 50.82

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About MLP Maui Land & Pineapple Company Inc.

Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales: , which includes land planning and entitlement, development, and sales activities.; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.

Share on Social Networks: